|
Post by lovie350z on Jun 11, 2018 12:51:32 GMT
|
|
|
Post by jckrdu on Jun 11, 2018 14:20:17 GMT
Flag pattern is showing on the 3 month chart. Need a little more volume - institutional buying - to start trading over $1.90. If that happens, the traders that use Technical Analysis (TA) will likely see that as a break-out from the flag pattern (and they'll start piling in IMO), where somewhere north of $2 should be the next stop.
|
|
|
Post by selluwud on Jun 13, 2018 17:49:34 GMT
Down graded by Jeffires today and taking a hit. -10%
|
|
|
Post by lcd on Jul 12, 2018 20:08:31 GMT
I made a big mistake chasing this stock down between $5 and $2. I am seriously thinking about just cutting my losses. Anyone here want to convince me to stick it out?
|
|
|
Post by lovie350z on Jul 12, 2018 20:19:58 GMT
|
|
|
Post by lovie350z on Jul 13, 2018 12:14:12 GMT
|
|
|
Post by JHam on Jul 13, 2018 12:35:54 GMT
Wow. Congrats to all who have been buying while this was in the dumps.
|
|
|
Post by lcd on Jul 13, 2018 13:23:02 GMT
That $2.59 price didn't last long. It is still up about 35% heading into the open, but I am averaged in at $3.73 and I don't expect see that pps again anytime soon, but I suppose I will watch this over the next week to see if it continues to rebound or if I should just cut my losses.
|
|
|
Post by jckrdu on Jul 13, 2018 16:17:59 GMT
Sold half my remaining position pre-market over $2, and the rest at $1.50 after the open. While this was a losing trade, I'm keeping my eye on ADXS as I like their Neoantigen focus. Check out market cap of Phase 1 Neoantigen company NTGN that just did an IPO.
Still upside potential if they close a partnership for their lead AXAL/Cervical program in Phase 3, but CEO is on record that they'll wind it down if no partner surfaces in "limited time". Don't like that risk.
|
|
|
Post by lcd on Sept 7, 2018 12:55:18 GMT
|
|
|
Post by selluwud on Sept 7, 2018 14:07:31 GMT
I guess their therapy is not what it was cracked up to be? Circling the drain?
|
|
|
Post by jckrdu on Sept 21, 2018 15:51:37 GMT
Sold half my remaining position pre-market over $2, and the rest at $1.50 after the open. While this was a losing trade, I'm keeping my eye on ADXS as I like their Neoantigen focus. Check out market cap of Phase 1 Neoantigen company NTGN that just did an IPO. Still upside potential if they close a partnership for their lead AXAL/Cervical program in Phase 3, but CEO is on record that they'll wind it down if no partner surfaces in "limited time". Don't like that risk. Per my last message in July, I sold all my ADXS in July as I saw additional risks on the horizon. Over the last few days, I re-established a position in ADXS at .81 and .82. Guidance is that the new CEO is still "seeking a partner" for the lead AXAL/Cervical program. The fact that he hasn't shut the program down yet can be taken as a luke-warm positive. Any news of an AXAL/cervical deal or that "discussions are proceeding" will cause the stock to sharply rebound. Still risks here if program is shutdown.
|
|
|
Post by selluwud on Dec 14, 2018 15:10:07 GMT
|
|
|
Post by lcd on Dec 14, 2018 15:33:19 GMT
I understand and share some of the concern about O'Connor since I hold a large chunk of Onosec shares, but he was hired there because he could close deals with partners. Everyone in biotech knows that most new drugs fail so I don't think he is a charlatan because he got big pharma to buy into one failed product.
That said it is sad to see ADXS hit new 52-week lows every week.
|
|